Arcutis Biotherapeutics, Inc. (ARQT)
24.79
-0.29
(-1.16%)
USD |
NASDAQ |
Aug 24, 16:00
24.79
0.00 (0.00%)
After-Hours: 20:00
Arcutis Biotherapeutics Enterprise Value : 3.025B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 3.025B |
| August 20, 2026 | 3.059B |
| August 19, 2026 | 3.198B |
| August 18, 2026 | 3.208B |
| August 17, 2026 | 3.092B |
| August 14, 2026 | 3.165B |
| August 13, 2026 | 3.119B |
| August 12, 2026 | 3.176B |
| August 11, 2026 | 3.170B |
| August 10, 2026 | 3.131B |
| August 07, 2026 | 3.051B |
| August 06, 2026 | 3.195B |
| August 05, 2026 | 3.279B |
| August 04, 2026 | 3.144B |
| August 03, 2026 | 3.133B |
| July 31, 2026 | 3.249B |
| July 30, 2026 | 3.391B |
| July 29, 2026 | 3.374B |
| July 28, 2026 | 3.445B |
| July 27, 2026 | 3.372B |
| July 24, 2026 | 3.310B |
| July 23, 2026 | 3.308B |
| July 22, 2026 | 3.379B |
| July 21, 2026 | 3.424B |
| July 20, 2026 | 3.333B |
| Date | Value |
|---|---|
| July 17, 2026 | 3.453B |
| July 16, 2026 | 3.359B |
| July 15, 2026 | 3.364B |
| July 14, 2026 | 3.242B |
| July 13, 2026 | 3.281B |
| July 10, 2026 | 3.359B |
| July 09, 2026 | 3.490B |
| July 08, 2026 | 3.455B |
| July 07, 2026 | 3.350B |
| July 06, 2026 | 3.149B |
| July 02, 2026 | 3.117B |
| July 01, 2026 | 3.121B |
| June 30, 2026 | 3.168B |
| June 29, 2026 | 3.236B |
| June 26, 2026 | 3.266B |
| June 25, 2026 | 3.228B |
| June 24, 2026 | 3.313B |
| June 23, 2026 | 3.175B |
| June 22, 2026 | 3.224B |
| June 18, 2026 | 3.168B |
| June 17, 2026 | 3.169B |
| June 16, 2026 | 3.100B |
| June 15, 2026 | 3.089B |
| June 12, 2026 | 2.939B |
| June 11, 2026 | 2.965B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.195B |
| Insmed, Inc. | 27.04B |
| Emergent BioSolutions, Inc. | 707.90M |
| Exelixis, Inc. | 12.79B |
| Vertex Pharmaceuticals, Inc. | 132.96B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 15.01M |
| Revenue (Quarterly) | 129.86M |
| Total Expenses (Quarterly) | 114.85M |
| EPS Diluted (Quarterly) | 0.1104 |
| Gross Profit Margin (Quarterly) | 91.58% |
| Profit Margin (Quarterly) | 11.56% |
| Earnings Yield | 0.84% |
| Operating Earnings Yield | 1.04% |
| Normalized Earnings Yield | 0.8371 |